Trial Profile
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary) ; Naltrexone (Primary) ; Naltrexone (Primary)
- Indications Opioid-related disorders
- Focus Therapeutic Use
- 09 Jul 2021 Status changed from recruiting to completed.
- 29 Jan 2021 Planned End Date changed from 31 Dec 2020 to 31 May 2021.
- 29 Jan 2021 Planned primary completion date changed from 31 Dec 2020 to 31 May 2021.